Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554061 | 0.86 | REN (0.64) | RENCYP3A4CYP2D6 | |
| SCHEMBL20474604 | 0.86 | REN (0.64) | RENCYP3A4CYP2D6 | |
| SCHEMBL14598317 | 0.86 | MEN1 (0.52) | TLR2MMEL1MEN1ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6896628 | 0.85 | REN (0.62) | RENCYP3A4CYP2D6 | |
| SCHEMBL29300391 | 0.82 | REN (0.59) | REN | |
| SCHEMBL29300413 | 0.81 | DPP7 (0.58) | RENTLR2 | |
| SCHEMBL31303644 | 0.81 | CYP3A4 (0.49) | MEN1ALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL27163859 | 0.79 | REN (0.60) | REN | |
| SCHEMBL3409209 | 0.79 | REN (0.60) | REN | |
| SCHEMBL987969 | 0.79 | REN (0.60) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | REN 1943/4885TLR2 2440/4885MMEL1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.